EMS
MCID: ESN002
MIFTS: 42

Eosinophilia-Myalgia Syndrome (EMS) malady

Categories: Rare diseases, Blood diseases

Aliases & Classifications for Eosinophilia-Myalgia Syndrome

Aliases & Descriptions for Eosinophilia-Myalgia Syndrome:

Name: Eosinophilia-Myalgia Syndrome 12 50 52 42 14 69
Ems 50 3
Syndrome with Inflammatory and Autoimmune Components That Affect the Skin, Fascia, Muscle, Nerve, Blood Vessels, Lung, and Heart 50
Severe Muscle Pain and Abnormally High Eosinophils 50
Eosinophilia Myalgia Syndrome 12
L-Tryptophan Induced Ems 50

Classifications:



External Ids:

Disease Ontology 12 DOID:998
ICD9CM 35 710.5
MeSH 42 D016603
SNOMED-CT 64 95416007
UMLS 69 C0085179

Summaries for Eosinophilia-Myalgia Syndrome

CDC : 3 Emergency medical services (EMS) workers provide pre-hospital emergency medical care. Their duties create an inherent risk for on-the-job injuries and illnesses. Research shows that EMS workers have high rates of fatal injuries and nonfatal injuries and illnesses.

MalaCards based summary : Eosinophilia-Myalgia Syndrome, also known as ems, is related to hepatitis and toxic oil syndrome, and has symptoms including muscle cramp, muscle rigidity and muscle spasticity. An important gene associated with Eosinophilia-Myalgia Syndrome is IL5 (Interleukin 5), and among its related pathways/superpathways are Allograft rejection and Immune response NFAT in immune response. The drugs 5-hydroxytryptophan and Tryptophan have been mentioned in the context of this disorder. Affiliated tissues include skin, heart and lung.

Wikipedia : 71 Eosinophilia–myalgia syndrome (EMS) is an incurable and sometimes fatal flu-like neurological... more...

Related Diseases for Eosinophilia-Myalgia Syndrome

Diseases related to Eosinophilia-Myalgia Syndrome via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
id Related Disease Score Top Affiliating Genes
1 hepatitis 29.9 HLA-DRB1 IFNG
2 toxic oil syndrome 10.5
3 fasciitis 10.5
4 eosinophilic fasciitis 10.3
5 cataract, total congenital 10.2 IFNG IL5
6 spastic diplegia 10.2 IFNG IL5
7 multiple epiphyseal dysplasia due to collagen 9 anomaly 10.2 IFNG IL5
8 urethral intrinsic sphincter deficiency 10.2 IFNG IL5
9 hemangioma of spleen 10.2 IFNG IL5
10 acute gonococcal prostatitis 10.2 IFNG IL5
11 cutaneous fibrous histiocytoma 10.2 IFNG IL5
12 peptidic growth factors deficiency 10.2 HLA-DRB1 IL5
13 multiple mitochondrial dysfunctions syndrome 10.2 IFNG IL5
14 hemoglobin d disease 10.2 HLA-DQA1 HLA-DRB1
15 bilateral parasagittal parieto-occipital polymicrogyria 10.2 HLA-DQA1 HLA-DRB1
16 abnormal retinal correspondence 10.2 IFNG IL5
17 kernicterus due to isoimmunization 10.2 HLA-DQA1 HLA-DRB1
18 cervical adenoid basal carcinoma 10.2 HLA-DQA1 HLA-DRB1
19 hydrophthalmos 10.2 IFNG IL5
20 caplan's syndrome 10.1 HLA-DRB1 IFNG
21 hyperlucent lung 10.1 HLA-DQA1 IFNG
22 loiasis 10.1 IFNG IL5
23 distal trisomy 14q 10.1 HLA-DRB1 IFNG
24 oromandibular dystonia 10.1 HLA-DQA1 HLA-DRB1
25 autosomal recessive congenital methemoglobinemia 10.1 IFNG IL5
26 polyneuropathy 10.1
27 clostridium difficile colitis 10.1 HLA-DRB1 IFNG
28 benign meningioma 10.1 IDO1 IL5
29 acanthoma 10.1 HLA-DRB1 IFNG
30 pancreatic signet ring cell adenocarcinoma 10.1 HLA-DRB1 IFNG
31 autoimmune disease of skin and connective tissue 10.1 HLA-DQA1 IFNG
32 hereditary alpha tryptasemia syndrome 10.1 HLA-DRB1 IFNG
33 ragweed sensitivity 10.1 HLA-DQA1 HLA-DRB1
34 benign deep fibrous histiocytoma 10.1 HLA-DRB1 IFNG
35 plummer's disease 10.1 HLA-DRB1 IFNG
36 variola minor 10.1 IDO1 IFNG
37 peripheral artery disease 10.1 HLA-DQA1 HLA-DRB1
38 mansonelliasis 10.1 IFNG IL5
39 chronic thromboembolic pulmonary hypertension 10.1 IDO1 IFNG
40 tracheitis 10.1 IFNG IL5
41 myopathy 10.1
42 neuropathy 10.1
43 stiff-person syndrome 10.1 HLA-DRB1 IFNG
44 balkan nephropathy 10.1 IFNG IL5
45 heart conduction disease 10.1 HLA-DRB1 IFNG
46 depressed scar 10.0 HLA-DRB1 IFNG
47 paratyphoid fever 10.0 IFNG IL5
48 inflammatory bowel disease 2 10.0 IFNG IL5
49 gastroschisis abdominal wall defects, included 10.0 AHR IFNG IL5
50 disease of mental health 10.0 HLA-DRB1 IFNG IL5

Graphical network of the top 20 diseases related to Eosinophilia-Myalgia Syndrome:



Diseases related to Eosinophilia-Myalgia Syndrome

Symptoms & Phenotypes for Eosinophilia-Myalgia Syndrome

UMLS symptoms related to Eosinophilia-Myalgia Syndrome:


muscle cramp, muscle rigidity, muscle spasticity, muscle weakness, myalgia

Drugs & Therapeutics for Eosinophilia-Myalgia Syndrome

Drugs for Eosinophilia-Myalgia Syndrome (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):


id Name Status Phase Clinical Trials Cas Number PubChem Id
1 5-hydroxytryptophan
2 Tryptophan Nutraceutical

Interventional clinical trials:


id Name Status NCT ID Phase
1 L-5-HTP-Related EMS Completed NCT00001918
2 Survey of the Use of Alternative Medical Therapies in Adult Cancer Patients Enrolled in Phase I Clinical Trials Completed NCT00001695

Search NIH Clinical Center for Eosinophilia-Myalgia Syndrome

Cochrane evidence based reviews: eosinophilia-myalgia syndrome

Genetic Tests for Eosinophilia-Myalgia Syndrome

Anatomical Context for Eosinophilia-Myalgia Syndrome

MalaCards organs/tissues related to Eosinophilia-Myalgia Syndrome:

39
Skin, Heart, Lung, Brain, T Cells, Neutrophil, Liver

Publications for Eosinophilia-Myalgia Syndrome

Articles related to Eosinophilia-Myalgia Syndrome:

(show top 50) (show all 338)
id Title Authors Year
1
Post-epidemic eosinophilia-myalgia syndrome associated with L-tryptophan. ( 21702023 )
2011
2
AHR activation by tryptophan--pathogenic hallmark of Th17-mediated inflammation in eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome? ( 19941898 )
2010
3
Immunogenetic risk and protective factors for the development of L-tryptophan-associated eosinophilia-myalgia syndrome and associated symptoms. ( 19790128 )
2009
4
Part II. Eosinophilia-Myalgia Syndrome: further correlations between compromised histamine degradation, eosinophilias and myopathies. ( 17806156 )
2007
5
Generation of quinoneimine intermediates in the bioactivation of 3-(N-phenylamino)alanine (PAA) by human liver microsomes: a potential link between eosinophilia-myalgia syndrome and toxic oil syndrome. ( 17892268 )
2007
6
Calcinosis cutis in a patient with eosinophilia-myalgia syndrome: case report. ( 16838769 )
2006
7
A heretofore undisclosed crux of eosinophilia-myalgia syndrome: compromised histamine degradation. ( 16307217 )
2005
8
Non-L-tryptophan related eosinophilia-myalgia syndrome with hypoproteinemia and hypoalbuminemia. ( 12610828 )
2003
9
Rigorous new approach to constructing a gold standard for validating new diagnostic criteria, as exemplified by the eosinophilia-myalgia syndrome. ( 11606145 )
2001
10
Eosinophilic cholecystitis as a possible late manifestation of the eosinophilia-myalgia syndrome. ( 11147758 )
2000
11
Eosinophilia-myalgia syndrome case-associated contaminants in commercially available 5-hydroxytryptophan. ( 10721089 )
1999
12
Eosinophilia-myalgia syndrome and giant cell myocarditis: a case report and therapeutic approach. ( 11720607 )
1999
13
Is there any relationship between eosinophilia myalgia syndrome (EMS) and fibromyalgia syndrome (FMS)? An analysis of clinical and immunological data. ( 10721092 )
1999
14
Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. ( 10606395 )
1999
15
Structural characterization of case-associated contaminants peak C and FF in L-tryptophan implicated in eosinophilia-myalgia syndrome. ( 10721088 )
1999
16
Rapid HPLC screening method for contaminants found in implicated L-tryptophan associated with eosinophilia myalgia syndrome and adulterated rapeseed oil associated with toxic oil syndrome. ( 9787895 )
1998
17
Pain, fatigue, and sleep in eosinophilia-myalgia syndrome: relationship to neuropsychological performance. ( 9706542 )
1998
18
On-line HPLC-tandem mass spectrometry structural characterization of case-associated contaminants of L-tryptophan implicated with the onset of eosinophilia myalgia syndrome. ( 9817085 )
1998
19
Neurologic, MR imaging, and MR spectroscopic findings in eosinophilia myalgia syndrome. ( 9802492 )
1998
20
L-tryptophan-related eosinophilia-myalgia syndrome possibly associated with a chronic B-lymphocytic leukemia. ( 9858150 )
1998
21
Structural characterization of contaminants found in commercial preparations of melatonin: similarities to case-related compounds from L-tryptophan associated with eosinophilia-myalgia syndrome. ( 9544622 )
1998
22
Eosinophilia-myalgia syndrome: selective cognitive impairment, longitudinal effects, and neuroimaging findings. ( 9408106 )
1997
23
The eosinophilia myalgia syndrome: to be or not to be. ( 9213375 )
1997
24
Eosinophilia-myalgia syndrome, eosinophilic fasciitis, and related fibrosing disorders. ( 9375286 )
1997
25
Elevated L-kynurenine level and its normalization by prednisolone in a patient with eosinophilia-myalgia syndrome. ( 9037890 )
1997
26
Eosinophilia myalgia syndrome. ( 9213377 )
1997
27
Eosinophilia-myalgia syndrome: description of an unusual case. ( 9196880 )
1997
28
Eosinophilia-myalgia syndrome: opportunities realized and missed. ( 9195545 )
1997
29
On-line HPLC-tandem mass spectrometry analysis of contaminants of L-tryptophan associated with the onset of the eosinophilia-myalgia syndrome. ( 9295237 )
1997
30
Increased activity of the alpha 1(I) procollagen promoter in skin fibroblasts from patients with chronic eosinophilia-myalgia syndrome. ( 9076948 )
1997
31
Cognitive deficits in a murine model of the eosinophilia-myalgia syndrome: a preliminary report. ( 8888024 )
1996
32
Analysis of Centers for Disease Control and Prevention criteria for the eosinophilia-myalgia syndrome in a geographically defined population. ( 8895183 )
1996
33
Eosinophilia-myalgia syndrome. Status of patients at onset and after four years of disease. ( 8906291 )
1996
34
A comparative study of tissue distribution and excretion among three substances implicated in eosinophilia-myalgia syndrome. ( 8906290 )
1996
35
Eosinophilia-myalgia syndrome: patient status 2-4 years after onset. ( 8895178 )
1996
36
A diagnostic algorithm for distinguishing the eosinophilia-myalgia syndrome from fibromyalgia and chronic myofascial pain. ( 8895177 )
1996
37
Eosinophilia-myalgia syndrome among the non-L-tryptophan users and pre-epidemic cases. ( 8895159 )
1996
38
1995 Bailey K. Ashford lecture. Public health lessons from two catastrophic epidemics: the toxic oil syndrome and the eosinophilia-myalgia syndrome. ( 8744866 )
1996
39
Pathophysiology of the eosinophilia-myalgia syndrome. ( 8895179 )
1996
40
Effect of L-tryptophan products on function of human eosinophils: investigation of the causal mechanisms of eosinophilia myalgia syndrome associated with L-tryptophan products. ( 8906111 )
1996
41
Tryptophan produced by Showa Denko and epidemic eosinophilia-myalgia syndrome. ( 8895184 )
1996
42
EBT, a tryptophan contaminant associated with eosinophilia myalgia syndrome, is incorporated into proteins during translation as an amino acid analog. ( 9161698 )
1996
43
Delayed onset of skin fibrosis after the ingestion of eosinophilia-myalgia syndrome-associated L-tryptophan. ( 8708033 )
1996
44
Pathogenesis of L-tryptophan eosinophilia myalgia syndrome. ( 8906284 )
1996
45
The eosinophilia-myalgia syndrome: what we know, what we think we know, and what we need to know. ( 8895175 )
1996
46
Persistent microvasculopathy in chronic eosinophilia-myalgia syndrome. ( 8906289 )
1996
47
Epidemiologic studies of the association of L-tryptophan with the eosinophilia-myalgia syndrome: a critique. ( 8895181 )
1996
48
Effects of tryptophan related compounds on nuclear regulatory control. Possible role in the eosinophilia-myalgia syndrome. ( 8906287 )
1996
49
Eosinophilia-Myalgia Syndrome: Review and Reappraisal of Clinical, Epidemiologic and Animal Studies Symposium. Washington, D.C., USA, December 7-8, 1994. Proceedings. ( 9053528 )
1996
50
Animal models of the eosinophilia-myalgia syndrome. ( 8895185 )
1996

Variations for Eosinophilia-Myalgia Syndrome

Expression for Eosinophilia-Myalgia Syndrome

Search GEO for disease gene expression data for Eosinophilia-Myalgia Syndrome.

Pathways for Eosinophilia-Myalgia Syndrome

Pathways related to Eosinophilia-Myalgia Syndrome according to GeneCards Suite gene sharing:

(show all 20)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
12.45 HLA-DQA1 HLA-DRB1 IFNG IL5
2
Show member pathways
12.32 HLA-DQA1 HLA-DRB1 IFNG
3
Show member pathways
12.22 HLA-DQA1 HLA-DRB1 IFNG
4 11.96 HLA-DQA1 HLA-DRB1 IFNG
5
Show member pathways
11.9 HLA-DQA1 HLA-DRB1 IFNG
6 11.86 HLA-DQA1 HLA-DRB1 IFNG
7
Show member pathways
11.56 AHR HLA-DQA1 HLA-DRB1 IFNG IL5
8 11.53 HLA-DQA1 HLA-DRB1 IL5
9 11.45 HLA-DQA1 HLA-DRB1 IFNG
10 11.44 HLA-DQA1 HLA-DRB1
11 11.34 AHR IFNG IL5
12 11.32 HLA-DQA1 HLA-DRB1
13 11.25 AHR IFNG
14 11.23 IFNG IL5
15 11.08 IDO1 IFNG
16 11.04 IFNG IL5
17 10.96 HLA-DRB1 IFNG
18 10.91 IFNG IL5
19 10.84 AHR IFNG IL5
20 10.61 HLA-DRB1 IFNG IL5

GO Terms for Eosinophilia-Myalgia Syndrome

Cellular components related to Eosinophilia-Myalgia Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 endocytic vesicle membrane GO:0030666 9.37 HLA-DQA1 HLA-DRB1
2 ER to Golgi transport vesicle membrane GO:0012507 9.32 HLA-DQA1 HLA-DRB1
3 transport vesicle membrane GO:0030658 9.26 HLA-DQA1 HLA-DRB1
4 clathrin-coated endocytic vesicle membrane GO:0030669 9.16 HLA-DQA1 HLA-DRB1
5 integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 8.96 HLA-DQA1 HLA-DRB1
6 MHC class II protein complex GO:0042613 8.62 HLA-DQA1 HLA-DRB1

Biological processes related to Eosinophilia-Myalgia Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 T cell receptor signaling pathway GO:0050852 9.5 HLA-DQA1 HLA-DRB1 IFNG
2 immune response GO:0006955 9.46 HLA-DQA1 HLA-DRB1 IFNG IL5
3 negative regulation of T cell proliferation GO:0042130 9.4 HLA-DRB1 IDO1
4 positive regulation of interleukin-12 production GO:0032735 9.37 IDO1 IFNG
5 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.26 HLA-DQA1 HLA-DRB1
6 interferon-gamma-mediated signaling pathway GO:0060333 9.13 HLA-DQA1 HLA-DRB1 IFNG
7 antigen processing and presentation GO:0019882 8.8 HLA-DQA1 HLA-DRB1 IFNG

Molecular functions related to Eosinophilia-Myalgia Syndrome according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 peptide antigen binding GO:0042605 8.96 HLA-DQA1 HLA-DRB1
2 MHC class II receptor activity GO:0032395 8.62 HLA-DQA1 HLA-DRB1

Sources for Eosinophilia-Myalgia Syndrome

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....